Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Combined RSV and COVID-19 Vaccine in Healthy Older Adults
NCT05886777Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2023
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-07960613 in coronavirus disease 2019 (COVID-19) and respiratory syncytial virus infection (RSV) (7 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Local Reactions at 7 days, Percentage of Participants With Systemic Events at 7 days and 7 more. Started Jun 2023; status: completed.
02
Drugs
PF-07960613
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05886777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886777.